CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
August 6th 2025
Following the June 2025 FDA approval of Datroway, Dr. Jacob A. Sands explained the significance of the regulatory approval for patients with lung cancer.
FDA Accepts Supplemental Biologics License Application for Tecentriq Combo in NSCLC
January 17th 2019The Food and Drug Administration has accepted Roche’s supplemental biologics license application for Tecentriq (atezolizumab) plus chemotherapy for the frontline treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.